Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Oct 26, 2023 9:40pm
149 Views
Post# 35703387

RE:Riders out

RE:Riders outI wish I was as positive as you, but it doesn't work like this.  The stock will continue to drop after dilution unless they surprise us with good news soon.  They burned existing shareholders, and additional new investors needed to drive the price higher (even to overcome the 25% drop experienced today alone due to dilution) will not buy in.  The market has a very long memory.  That is, unless they surprise on oncology or the acquisition of another licensing agreement.  There's been too many misteps to-date to think those are real posibilities until proven otherwise.  The stock is going to go into a longer period of anguish and likely further decline without a surpirse.  Paul and the rest of the leadership team lied, misled us, and didn't get the results they've outlined in their strategic plan.  Complete failures so far.  Why would new investors buy now?  It was already a lottery ticket.  Now it's a lottery ticket that can't be taken at face value.  Just when you've been told the odds are in your favor, they change them the day before.  Morons, every last one of them.  

I'm still holding on the hope that oncology produces something special.  Otherwise, this is completely dead money.  My losses are in the 92% range now.  It's not worth selling, and I have little hope they'll do anything meaningful at this point.

Greenviolino wrote:

So today was an opportunity for riders to get out of the issue, realizing the easy money is not happening. There is a lot of emotion being expressed on this board, understandingly so to a certain point. However, look at today's picture:
A few days ago, the company was valued at $75 million CAD market cap with around $20 million USD in cash.
Today, the same company is valued at $75 million CAD market cap with around $45 million USD in cash.
Trading at  almost cash/share. Which company would you buy?
Forget dilution, focus on numbers. 
And Lvesque is living on borrowed time. He will not survive this. 



<< Previous
Bullboard Posts
Next >>